Cases in Multiple Sclerosis Treatment: Evidence-Based Approaches to Optimal Care

Released: November 13, 2020

Expires: November 13, 2021

Provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education.

This activity is supported by an independent education grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hours
  • Pharmacists — 1.0 Contact Hours (.1 CEUs)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The target learning audience for this initiative is neurologists, nursing professionals, pharmacists, PAs, rehabilitation specialists, mental health professionals, and other members of the healthcare professional team who manage patients with multiple sclerosis.

Program Overview

Cases in Multiple Sclerosis Treatment: Evidence-Based Approaches to Optimal Care delivers timely and practical information on team-based strategies for optimizing disease modifying treatment for people living with MS. Expert faculty, Dr. Patricia K. Coyle, Dr. Clyde Markowitz, and Amy Perrin Ross, APN, review the latest evidence and discuss a series of case studies that illustrate common decision-making dilemmas related to starting, switching, and stopping disease-modifying therapy.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review evidence-based principles for setting treatment goals and starting disease-modifying therapy in patients diagnosed with MS
  • Employ approaches to evaluating treatment response and switching therapies when needed
  • Review considerations for stopping treatment in patients living with MS
  • Apply effective team-based strategies that promote optimal patient outcomes


Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Stony Brook University Hospital
Stony Brook, New York

Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Loyola University of Chicago MS Clinic
Oak Brook, IL

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation

The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMSC designates this activity for a maximum of 1.0 contact hours of continuing nursing education (1.0 in the area of pharmacology).

This knowledge-based activity, JA4008165-9999-20-057-H01-P, qualifies for 1.0 contact hours (.1 CEUs) of continuing pharmacy education credit.

Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. Paper certificates are not valid. For information about CPE Monitor, visit

Disclosures of Conflicts of Interest

Faculty Disclosures:

Patricia K. Coyle, MD, FAAN, FANA

  • Consulting Fees: Accordant, Biogen, Genentech, Sanofi Genzyme, GSK, Mylan, Novartis, Roche, EMD Serono, TG Therapeutics
  • Speakers Bureau: Biogen (unbranded talks)
  • Contracted Research: Actelion, Alkermes, Coronna LLD, Genentech/Roche, MedDay, NINDS, Novartis

Clyde E. Markowitz, MD

  • Consulting Fees: Actelion, Alexion, Bayer, Biogen, EMD Serono, Genentech/Roche, Sanofi Genzyme, Novartis, Teva

Amy Perrin Ross, APN

  • Consulting Fees: Alexion Biogen, EMD Serono, Genentech, Sanofi Genzyme, Novartis, Roche, Viela Bio
  • Speakers Bureau: Alexion Biogen, EMD Serono, Genentech, Sanofi Genzyme, Mallinckrodt, Novartis, Viela Bio

Accreditor and Planning Committee Disclosures:

June Halper, MSN, APN-C, MSCN, FAAN, has declared that she has no relevant financial relationships to disclose.

Laurie Scudder, DNP, NP, has declared that she has no relevant financial relationships to disclose.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who have control over content have disclosed no relevant financial relationships.

Publishing Staff Disclosures:

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control over content have disclosed no relevant financial relationships.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  • Read the CME/CE information and faculty disclosures.
  • Complete the pre-test
  • Participate in the online activity
  • Complete the post-test with a score of 75% or higher; you may take the post-test as many times as required to successfully complete
  • Complete the evaluation

Certificates will be emailed to the participant

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CME/CE credit. This information is provided to activity collaborators for the purposes of CME/CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.

Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.

Contact Information

For questions about this activity, please contact Catamount Medical Education at: [email protected].

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts